Literature DB >> 18708397

Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.

Fay Kastrinos1, Elena M Stoffel, Judith Balmaña, Ewout W Steyerberg, Rowena Mercado, Sapna Syngal.   

Abstract

BACKGROUND AND AIMS: Lynch syndrome is caused by germ-line mismatch repair gene mutations. We examined the phenotypic differences between MLH1 and MSH2 gene mutation carriers and whether mutation type (point versus large rearrangement) affected phenotypic expression.
METHODS: This is a cross-sectional prevalence study of 1,914 unrelated probands undergoing clinical genetic testing for MLH1 and MSH2 mutations at a commercial laboratory.
RESULTS: Fifteen percent (285 of 1,914) of subjects had pathogenic mutations (112 MLH1, 173 MSH2). MLH1 carriers had a higher prevalence of colorectal cancer (79% versus 69%, P = 0.08) and younger mean age at diagnosis (42.2 versus 44.8 years, P = 0.03) than MSH2 carriers. Forty-one percent of female carriers had endometrial cancer and prevalence was similar in both groups. Other cancers were more frequent in MSH2 carriers (24% versus 9%, P = 0.001) and their families (P < 0.001). Multivariable analyses confirmed these associations. Of the 1,016 subjects who underwent Southern blot analysis, 42 had large rearrangements (7 MLH1, 35 MSH2). There were no phenotypic differences between carriers with large rearrangements and point mutations.
CONCLUSIONS: In this large study of mismatch repair gene mutation carriers from the United States, MLH1 carriers had more colorectal cancer than MSH2 carriers whereas endometrial cancer prevalence was similar. Large genomic rearrangements were more frequent in the MSH2 gene. MSH2 carriers and their relatives have more extracolonic nonendometrial Lynch syndrome-associated cancers and may benefit from additional screening.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708397     DOI: 10.1158/1055-9965.EPI-08-0301

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  26 in total

1.  Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.

Authors:  Andreas Obermair; Danny R Youlden; Joanne P Young; Noralane M Lindor; John A Baron; Polly Newcomb; Susan Parry; John L Hopper; Robert Haile; Mark A Jenkins
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

2.  The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.

Authors:  Fay Kastrinos; Ewout W Steyerberg; Rowena Mercado; Judith Balmaña; Spring Holter; Steven Gallinger; Kimberly D Siegmund; James M Church; Mark A Jenkins; Noralane M Lindor; Stephen N Thibodeau; Lynn Anne Burbidge; Richard J Wenstrup; Sapna Syngal
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

3.  Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome.

Authors:  L H Katz; A M Burton-Chase; S Advani; B Fellman; K M Polivka; Y Yuan; P M Lynch; S K Peterson
Journal:  Clin Genet       Date:  2015-09-14       Impact factor: 4.438

Review 4.  Prophylactic surgery in Lynch syndrome.

Authors:  V Celentano; G Luglio; G Antonelli; R Tarquini; L Bucci
Journal:  Tech Coloproctol       Date:  2011-02-02       Impact factor: 3.781

5.  Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation.

Authors:  Patrizia Lastella; Margherita Patruno; Giovanna Forte; Alba Montanaro; Carmela Di Gregorio; Carlo Sabbà; Patrizia Suppressa; Adalgisa Piepoli; Anna Panza; Angelo Andriulli; Nicoletta Resta; Alessandro Stella
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

Review 6.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 7.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

Review 8.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

9.  DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.

Authors:  Sarah A Martin; Nuala McCabe; Michelle Mullarkey; Robert Cummins; Darren J Burgess; Yusaku Nakabeppu; Sugako Oka; Elaine Kay; Christopher J Lord; Alan Ashworth
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

10.  Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.

Authors:  Elena Stoffel; Bhramar Mukherjee; Victoria M Raymond; Nabihah Tayob; Fay Kastrinos; Jennifer Sparr; Fei Wang; Prathap Bandipalliam; Sapna Syngal; Stephen B Gruber
Journal:  Gastroenterology       Date:  2009-07-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.